Prostate Cancer - Results from #70

Preclinical Imaging of Prostate Cancer. March 9, 2023

DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial. March 8, 2023

Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy. March 8, 2023

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting. March 8, 2023

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis. March 8, 2023

Global Trends of Prostate Cancer by Age, and Their Associations With Gross Domestic Product (GDP), Human Development Index (HDI), Smoking, and Alcohol Drinking. March 8, 2023

Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. March 8, 2023

Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer. March 8, 2023

Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. March 7, 2023

Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. March 7, 2023

Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer. March 7, 2023

Prostate MRI and image Quality: It is time to take stock. March 7, 2023

Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis. March 7, 2023

Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients. March 7, 2023

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. March 7, 2023

A Polygenic Risk Score for Prostate Cancer Risk Prediction. March 7, 2023

MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. March 7, 2023

The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging. March 7, 2023

LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer. March 7, 2023

The Optimal Prostate Biopsy in the Era of Multiparametric Magnetic Resonance Imaging March 6, 2023

Page 4 of 1288